|This article needs additional citations for verification. (November 2016) (Learn how and when to remove this template message)|
|Traded as||NYSE: CBM
S&P 600 Component
|Founded||New Jersey (1981)|
|Headquarters||East Rutherford, NJ|
|Steven M. Klosk, CEO, President,|
|Revenue||433.9 million USD (2015)|
|57.2 million USD (2015)|
|Total assets||505.5 million USD (2015)|
|Total equity||310.8 million USD (2015)|
Number of employees
Cambrex is an innovative life sciences company that provides pharmaceutical products, expertise and technologies that accelerate small molecule therapeutics into markets across the world.
With over 35 years of active pharmaceutical ingredient (API) development and manufacturing expertise, a team of more than 1,200 experts and a strong presence in the USA and Europe, Cambrex is tried and trusted across branded and generic API markets.
Its custom development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances.
Cambrex has a presence in seven locations globally, including a corporate headquarters in East Rutherford, NJ, USA and API development and manufacturing facilities in Charles City, Iowa, USA, High Point, North Carolina, USA, Karlskoga, Sweden, Paullo (Milan), Italy, Tallinn, Estonia and Wiesbaden, Germany.
Originally named CasChem, the company was founded when the castor oil and derivatives product lines were acquired from NL Industries. In 1987, the company changed its name to Cambrex Corporation and became listed on the NASDAQ. In 1990, Cambrex became listed on the New York Stock Exchange (NYSE).
In 1991, Cambrex entered the life sciences arena with the acquisition of Salsbury Chemicals, a manufacturer of bulk intermediates and APIs, as well as high-level research in nitration chemistry, and Zeeland Chemicals, producer of specialty intermediates and hydrogenation chemistry. The Charles City site was established.
In 1995, Cambrex further penetrated the pharmaceutical market with the acquisition of the Nobel Pharma Chemistry businesses, Nobel Chemicals AB and Profarmaco S.r.l., located in Karlskoga, Sweden and Paullo, Milan, Italy.
Cambrex obtained DEA licensing for controlled substance API manufacturing in 2001. By 2008, Cambrex expanded its group of R&D chemists by acquiring Prosyntest in Tallinn, Estonia. Steven Klosk was appointed as CEO whilst remaining President. Cambrex Charles City also completed the addition of a high potency development center.
In 2009, Cambrex Paullo, (Milan), Italy completed the addition of a new cGMP API production facility.
To broaden its biocatalysis offering, in 2010, Cambrex acquired IEP GmbH in Wiesbaden Germany.
In 2013, Cambrex Charles City completed a major 7,000 sq. ft. facility expansion to increase API manufacturing capabilities for both existing products and a new product. In 2015, Cambrex completed a further expansion of a 45,000 sq. ft. temperature and humidity controlled cGMP warehouse space at Cambrex Charles City.
In 2016, Cambrex significantly expanded its cGMP API manufacturing and storage capabilities in Charles City, Iowa. The company also increased its large scale manufacturing capability in Karlskoga, Sweden, with the installation of new multi-purpose reactors and control room upgrades. During this time, Cambrex also opened a new pilot plant at its site in Paullo (Milan) Italy, allowing greater speed and flexibility for small scale API production.
In late 2016, Cambrex expanded its clinical stage API capabilities with the acquisition of PharmaCore, Inc. in High Point, North Carolina, a leading early phase chemistry specialist with expertise in developing, scaling up and manufacturing small molecule APIs for clinical phase projects.